Literature DB >> 27017162

Comparison of Modified Blumgart pancreaticojejunostomy and pancreaticogastrostomy after pancreaticoduodenectomy.

Shin-E Wang1, Shih-Chin Chen1, Bor-Uei Shyr1, Yi-Ming Shyr2.   

Abstract

BACKGROUND: The aim of this study was to compare perioperative outcomes after Blumgart pancreaticojejunostomy (PJ) and pancreaticogastrostomy (PG) for pancreatic-enteric reconstruction following pancreaticoduodenectomy.
METHODS: Data of patients undergoing Blumgart PJ and PG were retrieved from prospectively-collected database. Matched patients in each surgical groups were included based on the Callery risk scoring system for clinically relevant postoperative pancreatic fistula (CR-POPF) (grades B and C). Surgical parameters and risks were compared between these two groups.
RESULTS: A total of 206 patients undergoing PD were included. Blumgart PJ was associated with shorter postoperative hospital stay (median (range) 25 (10-99) vs. 27 (10-97) days, P = 0.022). There was no surgical mortality in the Blumgart PJ group, but a 4.9% perioperative mortality in the PG, P = 0.030. The CR-POPF by Blumgrt PG is significantly lower than that by PG for overall patients (7% vs. 20%, P = 0.007), especially for those in intermediate fistula risk zone (6% vs. 21%, P =0.048) and high fistula risk zone (14% vs. 47%, P=0.038).
CONCLUSIONS: Blumgart PJ is superior to PG in terms of pancreatic leakage and surgical mortality. Blumgart PJ can be recommended for pancreatic reconstruction after PD for all pancreatic remnant subtypes.
Copyright © 2015 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 27017162      PMCID: PMC4814607          DOI: 10.1016/j.hpb.2015.09.007

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  26 in total

1.  Pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy: a meta-analysis of randomized controlled trials.

Authors:  WeiTao Que; HongBo Fang; Bing Yan; Jie Li; WenZhi Guo; WenLong Zhai; ShuiJun Zhang
Journal:  Am J Surg       Date:  2015-01-22       Impact factor: 2.565

Review 2.  Meta-analysis of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy.

Authors:  J J Xiong; C L Tan; P Szatmary; W Huang; N W Ke; W M Hu; Q M Nunes; R Sutton; X B Liu
Journal:  Br J Surg       Date:  2014-07-16       Impact factor: 6.939

3.  The impact of pancreaticojejunostomy versus pancreaticogastrostomy reconstruction on pancreatic fistula after pancreaticoduodenectomy: meta-analysis of randomized controlled trials.

Authors:  Julie Hallet; Francis S W Zih; Raymond G Deobald; Adena S Scheer; Calvin H L Law; Natalie G Coburn; Paul J Karanicolas
Journal:  HPB (Oxford)       Date:  2014-07-07       Impact factor: 3.647

4.  Isolated Roux loop pancreaticojejunostomy versus pancreaticogastrostomy after pancreaticoduodenectomy: a prospective randomized study.

Authors:  Ayman El Nakeeb; Emad Hamdy; Ahmad M Sultan; Tarek Salah; Waleed Askr; Helmy Ezzat; Mohamed Said; Mostaffa Abu Zeied; Tallat Abdallah
Journal:  HPB (Oxford)       Date:  2014-01-28       Impact factor: 3.647

5.  A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy.

Authors:  C J Yeo; J L Cameron; M M Maher; P K Sauter; M L Zahurak; M A Talamini; K D Lillemoe; H A Pitt
Journal:  Ann Surg       Date:  1995-10       Impact factor: 12.969

6.  Randomized clinical trial of pancreaticogastrostomy versus pancreaticojejunostomy on the rate and severity of pancreatic fistula after pancreaticoduodenectomy.

Authors:  J Figueras; L Sabater; P Planellas; E Muñoz-Forner; S Lopez-Ben; L Falgueras; C Sala-Palau; M Albiol; J Ortega-Serrano; E Castro-Gutierrez
Journal:  Br J Surg       Date:  2013-11       Impact factor: 6.939

7.  Gastric pH and amylase and safety for non-stented pancreaticogastrostomy.

Authors:  Yi-Ming Shyr; Cheng-Hsi Su; Chew-Wun Wu; Wing-Yiu Lui
Journal:  Hepatogastroenterology       Date:  2002 Nov-Dec

8.  Pancreaticogastrostomy is associated with significantly less pancreatic fistula than pancreaticojejunostomy reconstruction after pancreaticoduodenectomy: a meta-analysis of seven randomized controlled trials.

Authors:  Fu-Bao Liu; Jiang-Ming Chen; Wei Geng; Sheng-Xue Xie; Yi-Jun Zhao; Li-Quan Yu; Xiao-Ping Geng
Journal:  HPB (Oxford)       Date:  2014-06-03       Impact factor: 3.647

9.  Pancreaticogastrostomy is superior to pancreaticojejunostomy for prevention of pancreatic fistula after pancreaticoduodenectomy: an updated meta-analysis of randomized controlled trials.

Authors:  Benjamin Menahem; Lydia Guittet; Andrea Mulliri; Arnaud Alves; Jean Lubrano
Journal:  Ann Surg       Date:  2015-05       Impact factor: 12.969

10.  Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreaticoduodenectomy for pancreatic or periampullary tumours: a multicentre randomised trial.

Authors:  Baki Topal; Steffen Fieuws; Raymond Aerts; Joseph Weerts; Tom Feryn; Geert Roeyen; Claude Bertrand; Catherine Hubert; Marc Janssens; Jean Closset
Journal:  Lancet Oncol       Date:  2013-05-02       Impact factor: 41.316

View more
  13 in total

1.  Surgical, survival, and oncological outcomes after vascular resection in robotic and open pancreaticoduodenectomy.

Authors:  Bor-Uei Shyr; Shih-Chin Chen; Yi-Ming Shyr; Shin-E Wang
Journal:  Surg Endosc       Date:  2019-04-08       Impact factor: 4.584

2.  Outcome of 150 Consecutive Blumgart's Pancreaticojejunostomy After Pancreaticoduodenectomy.

Authors:  Mallika Tewari; R Mahendran; T Kiran; A Verma; V K Dixit; S Shukla; H S Shukla
Journal:  Indian J Surg Oncol       Date:  2018-10-27

3.  Pancreaticojejunostomy With Externalized Stent vs Pancreaticogastrostomy With Externalized Stent for Patients With High-Risk Pancreatic Anastomosis: A Single-Center, Phase 3, Randomized Clinical Trial.

Authors:  Stefano Andrianello; Giovanni Marchegiani; Giuseppe Malleo; Gaia Masini; Alberto Balduzzi; Salvatore Paiella; Alessandro Esposito; Luca Landoni; Luca Casetti; Massimiliano Tuveri; Roberto Salvia; Claudio Bassi
Journal:  JAMA Surg       Date:  2020-04-01       Impact factor: 14.766

4.  Laparoscopic Pancreatoduodenectomy With Modified Blumgart Pancreaticojejunostomy.

Authors:  Matteo De Pastena; Jony van Hilst; Thijs de Rooij; Olivier R Busch; Michael F Gerhards; Sebastiaan Festen; Marc G Besselink
Journal:  J Vis Exp       Date:  2018-06-17       Impact factor: 1.355

5.  Technical Details and Results of a Modified End-to-Side Technique of Pancreatojejunostomy: a Personal Series of 100 Patients.

Authors:  Luca Morelli; Gregorio Di Franco; Simone Guadagni; Matteo Palmeri; Niccolò Furbetta; Desirée Gianardi; Marco Del Chiaro; Giulio Di Candio; Franco Mosca
Journal:  J Gastrointest Surg       Date:  2017-09-21       Impact factor: 3.452

6.  The vulnerable point of modified blumgart pancreaticojejunostomy regarding pancreatic fistula learned from 50 consecutive pancreaticoduodenectomy.

Authors:  Sung Geun Kim; Kwang Yeol Paik; Ji Seon Oh
Journal:  Ann Transl Med       Date:  2019-11

7.  Blumgart pancreaticojejunostomy: does it reduce postoperative pancreatic fistula in comparison to other pancreatic anastomoses?

Authors:  Marcello Di Martino; Ángela de la Hoz Rodríguez; Elena Martín-Pérez
Journal:  Ann Transl Med       Date:  2020-06

8.  Learning curves for robotic pancreatic surgery-from distal pancreatectomy to pancreaticoduodenectomy.

Authors:  Bor-Uei Shyr; Shih-Chin Chen; Yi-Ming Shyr; Shin-E Wang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

9.  Implication of pancreaticoenterostomy regarding postoperative pancreatic fistula.

Authors:  Kwang Yeol Paik
Journal:  Ann Transl Med       Date:  2020-05

10.  Comparison of pancreatojejunostomy techniques in patients with a soft pancreas: Kakita anastomosis and Blumgart anastomosis.

Authors:  Shoji Kawakatsu; Yosuke Inoue; Yoshihiro Mise; Takeaki Ishizawa; Hiromichi Ito; Yu Takahashi; Akio Saiura
Journal:  BMC Surg       Date:  2018-10-24       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.